HIV in the ICU

  • Alan S. Karstaedt
  • L. Rhudo Mathivha
  • Christine L. N. Banage
Part of the Perspective on Critical Care Infectious Diseases book series (CCID, volume 9)


In severely resource-limited settings, a number of questions will continue to vex ICU clinicians:
  1. 1.

    Should a patient’s HIV seropositivity disqualify the person from admission into an ICU? Individual hospitals and regional groups need to identify poor prognostic features and develop their own triage guidelines.

  2. 2.

    Most developing countries are not able to provide the patient with maintenance HAART once discharged from the ICU. Should this situation change, will providing expensive high-technology treatment to previously unrecognized as well as known AIDS patients become standard of care in developing countries?

  3. 3.

    How can one develop practices that do not discriminate against the HIV-infected while not squeezing out the HIV-non-infected?

  4. 4.

    What should be the relation and balance between a country’s efforts at preventing HIV infection and providing adequate care for those who have been infected?



Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Lactic Acidosis Human Immunodeficiency Virus Testing Nucleoside Reverse Transcriptase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS. Nature 2001; 410: 968–973.PubMedCrossRefGoogle Scholar
  2. 2.
    Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933–1942.PubMedGoogle Scholar
  3. 3.
    Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–860.Google Scholar
  4. 4.
    Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients with human immunodeficiency virus infection. Lancet 1998; 352:1725–1730.PubMedCrossRefGoogle Scholar
  5. 5.
    United Nations AIDS Programme. HIV/AIDS: the global epidemic. Geneva: United Nations AIDS Programme, 1998.Google Scholar
  6. 6.
    Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 2000; 160: 541–547.PubMedCrossRefGoogle Scholar
  7. 7.
    Watters DAK, Wilson IH. HIV infection, AIDS and ICU in Central Africa. Anaesthesia 1988; 43: 988–989.PubMedGoogle Scholar
  8. 8.
    Bhagwanjee S, Muckart DJJ, Jeena PM, Moodley P. Does HIV status influence the outcome of patients admitted to a surgical intensive care unit? A prospective double blind study. BMJ 1997; 314: 1077–1081.PubMedGoogle Scholar
  9. 9.
    Kale R. Commentary: failing to seek patients’ consent to research is always wrong. BMJ 1997; 314:1081–1082.Google Scholar
  10. 10.
    Bhagwanjee S, Muckart DJJ, Jeena PM, Moodley P. Commentary: why we did not seek informed consent before testing patients for HIV. BMJ 1997; 314:1082–1083.Google Scholar
  11. 11.
    Seedat YK. Commentary: no simple and absolute ethical rule exists for every conceivable situation. BMJ 1997; 314: 1083–1084.Google Scholar
  12. 12.
    Doyal L. Journals should not publish research to which patients have not given fully informed consent-with three exceptions. BMJ 1997; 314: 1107–1111.PubMedGoogle Scholar
  13. 13.
    Tobias JS. BMJ’s present policy (sometimes approving research in which patients have not given fully informed consent) is wholly correct. BMJ 1997; 314:1111–1114.PubMedGoogle Scholar
  14. 14.
    Anonymous. All treatment and trials must have informed consent. BMJ 1997; 314:1134–1135.Google Scholar
  15. 15.
    McKenzie AG. Outcome of patients with human immunodeficiency virus (HIV) infection admitted to intensive care: a preliminary study. Cent Afr J Med 1991; 37: 436–437.PubMedGoogle Scholar
  16. 16.
    Edge JM, Van der Merwe AE, Pieper CH, Bouic P. Clinical outcome of HIV positive patients with moderate to severe burns. Burns 2001; 27:111–114.PubMedCrossRefGoogle Scholar
  17. 17.
    Cornblath D. Treatment of the neuromuscular complications of human immunodeficiency virus infection. Ann Neurol 1988; 23(Suppl): S88–S91.PubMedGoogle Scholar
  18. 18.
    Cornblath D, McArthur J. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38: 794–796.PubMedGoogle Scholar
  19. 19.
    Cornblath D, Chaudhry V, Griffin J. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991; 30: 104–106.PubMedGoogle Scholar
  20. 20.
    Simpson DM, Olney RK. Peripheral neuropathies associated with human immunodeficiency virus infection. Neurol Clin 1992; 10: 685–711.PubMedGoogle Scholar
  21. 21.
    Schleicher GK, Richards GA, Black A. The effect of HIV on the outcome of patients admitted to the ICU with Guillain-Barre syndrome. Abstract 58; Combined Congress of the South African Thoracic Society and Critical Care Society of South Africa, Sun City 2002.Google Scholar
  22. 22.
    Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2,3,-didexyinosine (DDI). Ann Intern Med 1991; 115: 283–284.PubMedGoogle Scholar
  23. 23.
    John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717–723.PubMedGoogle Scholar
  24. 24.
    Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735–1744.PubMedGoogle Scholar
  25. 25.
    Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192–196.PubMedGoogle Scholar
  26. 26.
    Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34: 838–846.PubMedGoogle Scholar
  27. 27.
    Brinkman K, Vrouenraets S, Kauffmann R, Weigel HM, Frissen PHJ. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2001; 14: 2801–2802.Google Scholar
  28. 28.
    Soni N, Pozniak A. Continuing HIV therapy in the ICU. Crit Care 2001; 5: 247–248.PubMedCrossRefGoogle Scholar
  29. 29.
    Feeney C, Bryzman PA, Kong L, et al. T-lymphocyte subsets in acute illness. Crit Care Med 1995; 23: 1680–1685.PubMedGoogle Scholar
  30. 30.
    Centers for Disease control and Prevention. Updated U. S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for post-exposure prophylaxis. MMWR 2001; 50: (No RR-11):1–52.Google Scholar
  31. 31.
    Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337: 1485–1490.PubMedCrossRefGoogle Scholar
  32. 32.
    Karstaedt AS, Pantanowitz L. Occupational exposure of interns to blood in an area of high HIV seroprevalence. S Afr Med J 2001; 91: 57–61.PubMedGoogle Scholar
  33. 33.
    Ciesielski CA, Marianos D, Ou CY, et al. Transmission of HIV in a dental practice. Ann Intern Med 1992; 116: 798–805.PubMedGoogle Scholar
  34. 34.
    Transmission of HIV from an infected surgeon to a patient in France. Communicable Disease Report Weekly 1997 7: 17.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Alan S. Karstaedt
    • 1
  • L. Rhudo Mathivha
    • 1
  • Christine L. N. Banage
    • 1
  1. 1.Division of Infectious Diseases and Department of ICUChris Hani Baragwanath Hospital and University of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations